Aerovance inhales $38M for asthma drugs
Aerovance, developer of asthma medications, just brought in $38 million in a post-recapitalized third round of funding to push its lead drug candidate through a second phase of clinical trials. The company has already received $20 million, with the option of claiming the remaining $18 million as necessary.
Based in Berkeley, Calif., the company has already seen its drug, Aerovant, through the first part of second-phase trials. The company will use the new money to complete… Continue Reading
Optiscan adds $5M tranche for glucose monitor
Optiscan Biomedical, developer of a less-invasive human glucose monitor for hospitals, received an additional $5 million in a second round of funding that now totals $53 million. The boost came from Wexford Capital, reports VentureWire.
The Hayward, Calif.-based company plans to use its new resources to see its product through clinical trials next year. While it has already been tested on humans, it has yet to receive the stamp of approval from the Food and Drug… Continue Reading
Aerovance, asthma treatment company, finishes raising $60M
Aerovance, a Berkeley, Calif biopharmaceutical company looking to find a partner for its asthma treatement, Aerovant, reached back to year-old news and announced it has finished raising $60 million in a third round of financing.
There is “substantial very, very strong interest” by pharmaceutical and biotech companies in the asthma treatment, the company told VentureWire (sub required), though no specifics were given.
Here is the company’s announcement of the funding last year.
The company’s drugs target severe… Continue Reading